With Monsanto, Bayer will need more Aspirin

Activists protest against the acquisition of the U.S. agrochemical company Monsanto by the German Bayer company in Bonn, Germany, Friday, May 25, 2018. (AP Photo/Martin Meissner)

Even if Monsanto’s brands no longer exist as such, its legacy remains.

Monsanto, now a division of Bayer, has been ordered to pay a whopping US$289 million to a single American person, a former gardener, who developed cancer, allegedly through the use of their products.

Dewayne Johnson testified that he applied the product — Ranger Pro, a highly concentrated version of Roundup weedkiller, which contains glyphosate — 20 to 30 times per year while working as a school groundskeeper. He told a jury in San Francisco that he had two accidents at work, in which he was soaked with the product. In 2014, he was diagnosed with non-Hodgkin’s lymphoma.

Earlier this year, Bayer bought Monsanto for US$62 billion — all cash — in hopes to grow its business on both sides of the Atlantic and beyond. But even if Monsanto’s brands no longer exist as such, its legacy remains.

Given that 5,000 other similar cases regarding Roundup are currently in progress in the United States alone, Bayer will need to write a new chapter in its public relations playbook.

A mega-acquisition with tax benefits

Bayer bought Monsanto because it wanted its thriving crop science division to be complemented by Monsanto’s high-performing chemicals and pesticides. The potential of capitalizing on market dynamics and resolving dissimilar sale cycles between divisions also made the deal attractive, with the possibility of making revenues more predictable regardless of commodity prices.

Containers of Roundup, a weed killer made by Monsanto, are shown on a shelf at a hardware store in Los Angeles in 2017. (AP Photo/Reed Saxon, File)

And finally, given Germany’s lower tax rate versus that of the United States, the deal provided substantial tax benefits to Bayer. This mega-acquisition was generally well-received by the markets.

But Bayer did go in with a sobering and realistic approach regarding Monsanto. Knowing that Monsanto was damaged goods in the eyes of the public due to years of attacks and criticism by environmental groups, Bayer vowed to dump the name Monsanto as well as its brands while the products would remain the same.

Everyone — Monsanto most of all — wanted the name to disappear. Anyone who has ever Googled the word Monsanto will know that the name has been obliviated due to years of successful campaigning by influential voices.

The ‘Frankenfoods’ of ‘Monsatan’

Genetic engineering in agriculture has been a divisive issue for years now. Biotech companies, including Monsanto and Bayer, have been selling agricultural solutions to farmers for decades, but have only recently started to engage with the public.

By the time the sector realized it had never really received a “social licence” from the public to operate, it was too late, at least for Monsanto. Words like “Monsatan” and “Frankenfoods” were already widely used in media and social culture. Books, ads — most were manufactured to nurture some sort of collective hatred towards the St. Louis-based company.

This highly polarized public discourse points to the failure of the sector to properly communicate risks to the public, back when genetically modified crops were first produced in the early 1990s.

That political baggage is starting to sting now. After the California ruling, Bayer’s stock is in a nosedive. The California jury found Monsanto liable for selling glyphosate-based weed killers, including its Roundup brand, which according to certain studies causes cancer.

Uncertain cancer risk

It’s not clear whether glyphosate does cause cancer as there are several published studies suggesting the opposite. The Lancet, a reputable academic journal, and the International Agency for Research on Cancer have suggested that glyphosate may possibly cause cancer, but have never stated any clear conclusions on the issue.

The jury in California deliberated for more than three days before concluding that Monsanto did not provide enough information to the plaintiff about cancer risks. In other words, regardless of the science, doubts remain, which may have influenced the jury in favour of the plaintiff. Bayer will appeal, of course, but few really know where things will end up.

Throughout these litigations, what remains unknown is how Monsanto’s past could potentially contaminate Bayer’s 156-year-old history. Bayer and some other major players in the biotech sector were never really targeted by damaging crusades against genetically modified seeds and pesticides used in farming.

In the public eye, the California ruling could trigger a new movement, a shift against the sector’s new menace, Bayer. With many cases to come, Bayer’s communications department will only get busier.

This ruling signals, if anything, that consumers were taken for granted for far too long. Before the deal, while Monsanto was being viciously attacked, Bayer was merely an onlooker.

By virtue of well-known consumer brands, the German giant had historically more exposure to the public than Monsanto has ever had, but this will now likely warrant a new chapter in the company’s public relations playbook.

Sylvain Charlebois, Professor in Food Distribution and Policy, Dalhousie University

(This article was originally published on The Conversation. Read the original article.)

Comments